Announcement Pending on June 27 for “Best Selling Drug in Prescription Medicine History”

by Travis Johnson, Stock Gumshoe | June 18, 2012 11:33 am

Sniffing out the obesity drug teaser from Money Map Press

The good folks over at the Money Map Press are selling memberships in their “Passport Club” this week, and your impetus for signing up is that they will reveal their top-secret obesity drug that they think will be approved in about a week.

The Passport Club, by the way, is one of those “lifetime” offers that most of the big publishing houses (or at least, most of the ones that are affiliated with Agora) promote every now and then — you pay a big up-front fee ($4,750 in this case) and then get all (or almost all) of their newsletters for life, with no further charge except maybe $100 or so per year for “maintenance” and, for those who still mail, mailing costs.

(Here at Stock Gumshoe we also offer up a lifetime subscription option — we call it the “platinum” Irregulars membership [1]because the credit card companies we use get antsy when we use words like “lifetime,” which, in our case, means you get to be a paid member for as long as Stock Gumshoe exists. And who could imagine a world where Stock Gumshoe doesn’t exist? Of course, our option is only $200[2], and we don’t charge you any kind of “maintenance fee” — after all, this being the internet age, the 100th member doesn’t really cost us any more than the 99th.)

But I digress…. we were about to make you filthy rich, right? Or at least, find out which stock it is that the Money Map folks think will gild your lily. Here’s how they get our attention:

“For 15 Years Doctors Have Been Pleading, Unsuccessfully, With the FDA to Approve a Drug to Fight a Disease That, According to the World Health Organization, Affects as Many as 100 million Americans… and One Billion People Worldwide.

“On June 27th, They Could Finally Get It…

Paving the Way For What Some Experts Say Could Be The ‘Best Selling Drug in Prescription Medicine History'”

So yes, that “best selling drug in prescription medicine history” bit is not from me … and perhaps it’s not even from Money Map’s own lips, it’s from “some experts.”

But still, they say the decision is expected from the FDA on June 27 and it could be a massively popular drug, so that’s a near-term catalyst and just the kind of thing that can cause abrupt spurts in a stock, which means it’s just the kind of action that causes Scrooge McDuck dreams among investors and, therefore, makes for ad copy that undoubtedly sells newsletters very well.

What is this all about?

Well, they do reveal after a few pages of blather that it is an obesity drug — and you don’t need me (or five pages of charts and graphs) to tell you that obesity is probably the largest and most expensive health problem facing the United States, or that much of the world is likely following in our increasingly deep footprints on that path.

The teased upshot from the Money Mappers is that a third of Americans are potential customers for this drug, and perhaps as many as a billion people globally, numbers which would make Lipitor blush (Lipitor is in decline now thanks to the loss of its patent, but had about 15 years of sales that peaked at over $6 billion a year in just the U.S., the kind of numbers that every pharmaceutical executive mumbles about in his dreams).

Here are a few of the details from the teaser:

“Based on what we’ve found, we believe one drug in particular will break a long string of FDA denials and be approved on June 27th of this year – just a few days from now.

“When it happens, we expect the stock price of the tiny pharmaceutical company that developed this drug to jump substantially, handing you a very real opportunity to double or triple your investment in a matter of hours or days.

“There’s also significant long-term potential here, too.

“Right now, this company boasts a market cap of barely $1.5 billion – about 150th the size of drug giants Johnson & Johnson and Pfizer.

“Now, imagine you’ve just created a drug that 100 million people not only need… but have been waiting almost a decade to get their hands on…

“A drug doctors can’t wait to be able to prescribe to needy patients…

“This is why a number of experts believe it has all the makings of the next “super drug.”

“Even if the annual dosage price for this drug is just $1,250 per year (Lipitor cost north of $2,000 per year when Pfizer held an exclusive patent)… and if only one-tenth of the potential market uses the drug…

“That’s the potential for more than $12 billion in sales for just a single year – nearly $4 billion more than Lipitor’s average annual sales the past three years.”

And, as it’s the FDA and the Money Map folks undoubtedly have some lawyers on speed dial, they do include this disclaimer:

“… can we tell you for certain this will all unfold as we’re predicting, and on the date we’re anticipating?

“No, we can’t.

“As anyone in the drug development business will tell you, the FDA is notoriously unpredictable when it comes to drug approval.

“And even though we have very good reason to believe approval for at least one drug that treats this disease is a ‘slam dunk’ – the FDA has been particularly tough on similar drugs in the past.”

So … they “believe” it’s a slam dunk, but every once in a while the ball catches the rim and comes bouncing right out if you try to slam it too hard. Now that I would know, being not particularly gifted in the jumping department.

Why do they think that the FDA will approve the drug this time around? Well, it seems to be an argument of both efficacy and physician pressure … here’s how they describe it in the ad:

“For the better part of two decades now, they’ve been pressuring the Food and Drug Administration (FDA) – the group that vets the safety and effectiveness of newly developed drugs and grants marketing approval and conditions – to please, please approve any drug that can help curb it.

“And they’re frustrated that every drug that’s come before it that shows promise in dealing with disease has been denied.

“In fact, last year the American Society of Bariatric Physicians took the unprecedented step of publicly questioning the FDA for its refusal to approve what looked to be a series of promising drugs – saying the non-approval ‘handcuffs physicians’ who treat the disease.

“‘I was definitely disappointed,’ said ASBP president Dr. Larry Richardson. ‘This was the third drug the FDA has turned down in the last year or so, for one reason or another.’

“One doctor even called the FDA’s consideration of these drugs “unbalanced” compared to other drugs in terms of weighing the risk/reward factors.

“But today, doctors have good reason to believe their long wait will be over. Millions of Americans sick with the ailment are hopeful, too.

“Why so?

“Right now, there are two drugs up for approval in the coming weeks. And after examining the data from all Phase 3 studies, both received sought after “recommendations for approval” from the FDA’s highly influential Endocrinologic and Metabolic Drugs Advisory Committee.

“While the FDA is not bound to follow the Advisory Committee’s recommendations, they typically do. And the “yes” votes were overwhelming: 18 to 4 (and one abstention) for one drug… while the other drug being considered earned a 20-2 approval.

“Experts assume the panel recommended FDA approval of the drug based on two things:

“In one double-blind test involving 3,100 people with the disease, over half of them showed significant improvement – while those taking the placebo only fared half as well.”

So that’s the basic premise — which makes sense given the risk-averse nature of the FDA these days. The FDA can easily feel pressured to approve a drug that might save the lives of folks with late-stage lung cancer, for example, since side effects won’t matter much and the drug won’t reach hundreds of millions of people with unforeseen consequences. But for a non-acute “disease” like obesity, which won’t kill anyone overnight, you can easily see the qualms. It could easily be prescribed to millions of people in the first month who, will in need of weight loss, are not actually sick … which gives a great opportunity for any rare side effects to come out that might not have revealed themselves in the few thousand test patients in clinical trials, and they’d then be blamed for a drug that killed people quickly while treating a condition that kills very, very, very slowly and uncertainly.

The big picture argument for helping with the obesity epidemic is a clear one even if the wisdom of a drug-based “cure” is arguable for the bulk of the sufferers, but the risk aversion is greater than with drugs that have more acute life-saving demand in the fight against cancer or heart disease or whatever. So that’s the backdrop, and it has indeed led to many high-profile obesity drugs either being rejected or being told by the FDA to “go back to the clinic, try it on a few thousand more people, and come back in a couple years.”

So the Money Map folks note that there are two drugs in the pipeline for decisions coming inver the very near future, and that the first one is the better bet, with good efficacy and safety performance. Here’s how they hint out the last few details:

“Using the first drug that’s up for approval – the one our research suggests will the first to market and the No. 1 choice of doctors given its more favorable safety rating – overweight study subjects lost 5% of their body weight while on the drug….

“… people who kept taking the pill over the course of the study period kept the weight off – another key factor in the approval process….

“… aside from some headaches and reported dizziness, side effects were minor – according to a study published in the New England Journal of Medicine.

“That’s significant, because many past weight-loss pills have wreaked havoc on heart valve function.”

And that’s about all we see in the way of clues — but it’s plenty. Toss it all into the Thinkolator, and we find that this is our old friend … Arena Pharmaceuticals (ARNA), which was the subject of a bit of a newsletter showdown back in 2009[3], when they had an obesity drug that was on the verge of receiving happy news from the FDA.

Or not, as the case turned out. And yes, it was the same drug — lorcaserin — that caused ARNA’s previous bouts of stock market elevation, all of which have proved short-lived so far.

And yes, this falls in the category of, “would have been a better idea two weeks ago” — they got the positive vote from the FDA panel, sometimes called the “second to last step” of approval (though the FDA has certainly sometimes turned down drugs that were endorsed by these expert panels, and it was an 18-4 vote so it doesn’t have the extra weight of unanimity). That FDA panel vote led to the stock spiking to about $6 in May (it had been down around $2-3 before that), and it has been cruising upward in recent weeks and is now over $9. So I think we can assume that there’s a good bit of optimism built into the share price.

There’s also some precedence for the stock cratering after disappointing news from the FDA — in 2009 and 2010 it rode FDA anticipation up to $7 or so, then fell by 60-80% on bad news. 2011 was quiet as they gathered more clinical data, but now we’ve seen the optimism build to a crescendo again.

And though there is some risk profile at least whispered about with this stock — like a cancer risk with high levels of lorcaserin in mice, which the company claims is a result of massively higher levels than would result from regular use in humans — it does seem like the safety profile is making investors comfortable again. Whether that safety level is enough for the FDA to approve a drug that, on average, helps patients to lose and keep off something like 3-5% of their body weight, well, that’s the big question. And I can’t answer it.

But there is a catalyst looming on June 27 that will very likely be a huge event for the stock — if the news from the FDA is negative in any way, the stock should crater, and even with the optimism built in by a tripling in the stock price I’d assume that a real approval would still allow the stock to soar higher … after all, this has the potential of being the very definition of a blockbuster drug. I bet we’ll continue to see a lot of options traded on ARNA, as we have each time FDA decisions have been in the offing, but I have absolutely no idea which way it will go. The contrarian bet has gotten fairly inexpensive, as you can buy puts on ARNA for a loss of more than 50% at a decent price (about 50 cents for a $5 put, meaning you can profit if the stock drops by more than 50%), so that also might be a reasonable way to buy some downside insurance if you do decide to try to ride the stock on a positive decision.

Just to be clear, you can’t count on “stop loss” orders to protect yourself from events like the FDA decision, because any impact from the decision is likely to come extremely quickly — if word comes after the market close you could easily see the stock open 80% lower or 100% higher (I’m just making up those numbers, by the way) on June 28th, so the illusion of “protection” from a 15% stop loss doesn’t mean anything because such an order can’t catch a stock whose perceived value changes dramatically in one moment.

The other stock that’s on the verge of an FDA decision, and which has also gotten a favorable advisory panel vote, is Qnexa from Vivus (VVUS) — that decision is expected on July 17, and the advisory panel was even slightly more in favor for that one (20-2 vs 18-4). Vivus is substantially larger, about $2.6 billion market capitalization versus ARNA’s $1.6 billion, and has had a pretty similar ride over the last few years as the drug moved through the approval process in fits and starts, though it has been a bit less volatile — and Qnexa is also in Phase II trials for both diabetes and sleep apnea.

I don’t know whether these drugs will be approved, but the markets are certainly telling us that the odds are in their favor and the overwhelmingly massive size of the addressable market for these drugs means that even rash optimism among investors could possibly be rewarded if either of these drugs gets the expected green light. That said, if you do decide that the odds of approval have improved and either lorcaserin on June 27 or Qnexa in July 17 is worth your gamble, do take a quick look at the five-year charts of both ARNA and VVUS to get a quick sense of what the downside can be if you’re wrong. Just in case.

And, of course, tell us what you think — that little comment box at the bottom isn’t just for show, you know.

  1. “platinum” Irregulars membership :
  2. our option is only $200:
  3. subject of a bit of a newsletter showdown back in 2009:

Source URL:

  1. david
    Jun 18 2012, 12:07:10 pm

    well lets see let the fda approve High Fructose Corn Syrup as a huge ingredient in most processed foods and most soft drinks so then we need another drug to treat the resulting obesity epidemic that HFCS caused as the body does not recognise HFCS as food and sends it directly to the fat junkyard. What a business model!!!!

  2. Buddy
    Jun 18 2012, 12:22:44 pm

    It may be interesting to see whether any FDA insiders buy or short the stock at any time just prior to the announcement. Would be an indication of our being “protected”.

    • Mial
      Jun 18 2012, 12:39:34 pm

      Yes indeed but I doubt if you could ever find that information anywhere… This looks like a classic situation for a straddle surely? If there is a huge move, $10 July calls balanced by $10 July puts will give protection and result in an excellent return either way. (Need I add this is not investment advice!) Travis thanks for your research and good luck to all playing this one !

  3. CHRIS R
    Jun 18 2012, 12:23:57 pm

    Aren’t these the same knuckleheads that were pushing an abandoned graphite mine in Sweden a couple months ago, and they were so confident that they were going to give you $2500 to invest in this mine — oh pardon me, $2500 of my own money if I bought a $6500 membership in the first place. Yeah, $2500 of free money, is there no end to this kind of BS –CR

    • fred smith
      Jun 18 2012, 04:21:41 pm

      on approval, the stock price will probably double from here and some analysts have predicted $45 in the near future due to their deep pipeline of drug candidates.

  4. john g
    Jun 18 2012, 12:40:10 pm

    Thanks Travis,
    It’s just amazing that they want that kind of money when a stock has already more than doubled . It could end up another pump and dump deal or if approved may go up a few dollars more..

  5. Edward Maddox
    Jun 18 2012, 12:46:57 pm

    Money Map is rather late, huh? During May the stock went from $2 area to $6 region and now is already at $9.40 and bouncing around a few cents.

  6. James Coffeen
    Jun 18 2012, 12:48:56 pm

    You quoted them with “overweight study subjects lost 5% of their body weight while on the drug….”
    If people don’t keep on losing, but the 5% is the total effect, all they lose, a 230 pounder who loses 5% isn’t exactly a slim little thing.

  7. Mial
    Jun 18 2012, 12:57:12 pm

    After a bit of sleuthing of my own (OK I looked on Wikipedia) I found this…
    “On 10 May 2012, after a new round of studies submitted by Arena, an FDA panel voted to recommend lorcaserin with certain restrictions and patient monitoring. The restrictions include patients with a BMI of over 30, or with a BMI over 27 and a comorbidity like high blood pressure or type 2 diabetes.[6]”

    That’s quite a set of restrictions and will exclude a lot of, er, ‘lightness challenged’ people. If you are overweight then high blood pressure very often comes with the territory. Hmmm. I think I’ll just sit it out and hoover up a few crisps and beers as I watch the action.

    • 11057 |
      Travis Johnson, Stock Gumshoe
      Travis Johnson, Stock Gumshoe
      Jun 18 2012, 01:39:41 pm

      A BMI of 27-30 is not as restrictive as you might imagine — that’s probably about 25% of the population, maybe slightly less. I’m overweight but certainly not morbidly obese (about 6’3″, 225 lbs), and I come in with a BMI around 28. Blood pressure is a potential positive indicator for Arena — meaning, if they have high blood pressure or diabetes they can qualify for lorcaserin with a lower BMI. Not that I’m convinced this will be a miracle cure or a successful stock, just wanted to clarify that, so far, the restrictions leave a huge addressable population.

  8. Paul
    Jun 18 2012, 01:17:07 pm

    I couldn’t find the advisory committee meeting minutes on the FDA website; maybe they haven’t been posted yet. Without, it’s impossible to judge the weight of the arguments against approvel. The FDA presentation slides are available:
    Not a clearcut endorsement, but that doesn’t say anything either. For the long term prospects, even after approval, one would need to know much more, like: Did Arena sign away rights cheaply already for funding of their trials, what are the terms of any agreements ? Have they secured manufacturing or will there be a huge delay after approval, and possibly more rights to be given away for that matter ?

  9. Gary
    Jun 18 2012, 01:39:03 pm

    An obese 300 lb’er losing 5% of his/her body weight would still weigh 285 lb’s……Losing a mere 15 lbs. I would imagine the cost per pound of weight loss would be somewhat cost-equivalent to a “crystal meth” diet plan….and the side effects could potentially be as bad. (possible teeth discoloration, substance addiction, blood pressure spikes, etc…..

    My guess is the FDA isn’t gonna approve it

    • 11057 |
      Travis Johnson, Stock Gumshoe
      Travis Johnson, Stock Gumshoe
      Jun 18 2012, 01:48:12 pm

      Personally, I find the most effective short term technique is the “stomach flu weight loss” plan … but that’s just me.

        • Lorne Cutler
          Jun 19 2012, 11:20:25 am

          Years ago I used to travel to India on business. I often thought that you could market water from an Indian river as a weight loss regime. One or two drops everyday on your cerael or in your juice and the weight loss would be sure to follow. Now my plan had some mild side effects such as amoebic dysentry, but no drug is perfect. Used properly, it would probably get more than 15% of your weight off.

  10. Sharon Logue
    Jun 18 2012, 02:41:53 pm

    Very funny Travis….one of your best! VVUS has their Qnexa before European review in September. This drug is also in trial for Diabetes Type 2 and for Sleep apnea as well as weight loss. My money is on them. Sleep apnea may be the root cause. (No sleep, no oxygen, more stress = bad biochemistry) it’s also a 52 week high, so a straddle may work on this one out to Sept strikes.

  11. Myron Martin
    Myron Martin
    Jun 18 2012, 07:28:47 pm

    This would be amusing if it was not so ridiculous. WHY would anyone other than a nutritional ignoramous or self obsessed junk food addict elect to take a potentially harmful drug to control something that is self-inflicted in most cases, by bad food choices. Most people on a well balanced nutritionally adequate diet based on fruits and vegetables, nuts and whole grains, limited meat, (red in particular) modest dairy, minimally processed will not have an obesity problem. There is a reason that diabetes, heart disease, cancer are called “lifestyle diseases” which simply means making some intelligent choices will provide insurance against such outcomes. Maybe that is too simplistic for some, but any thinking person must come to grips with the FACTS, these problems were almost non-existent before our modern food processing days, that removed key vitamins and minerals from the natural foods our grandparents ate and substituted synthetic vitamins and preservatives and other chemical additives. etc. For just one example, at the turn of the century people ate mostly whole grains, in many cases ground fresh and this flour contained on average about 100 Int units of Vitamin E that has been shown by the Shute Bros and other researchers to protect heart health. The average diet today based on white flour is lucky to provide a tenth of that amount. Not difficult to make the connection if you do a little research.

  12. Ron4usc
    Jun 18 2012, 09:47:05 pm

    Two to three years ago I read in the paper (note not in an overpriced newsletter) that the FDA would be coming out with a letter to give a thumbs up or down for further study on Dendreon’s Provenge to treat prostate cancer. Note this was not approval/disapproval just a “we think it has potential or not”letter. I decided to do a small, fun-size, straddle using the front month options which expired only a few days after L-Day (letter day). DNDN was trading around 6 or 7 at the time if I remember right. L-Day morning a switched on CNBC and seeming every other trade on the ticker was DNDN: up $13, up $16, up $19. As soon as the market opened I sold my calls and reaped enough money to support my Starbucks habit for a few months.
    I later read the FDA’s letter and the phrase “damning with faint praise” came to mind. I was glad I sold, but the stock ran on up to the mid 30s! It later retreated below $10.

    So, my advise is to stop using logic about how much good the drug would do. If it’s like the DNDN situation, the runup or rundown will be strictly emotional and will overshoot drastically. With DNDN, I put equal $ into the put and call sides. With this one, I might bias a bit toward the put side since the stock has run up so much. I also will do a close to the money straddle like July 8 puts and July 10 calls. It costs more, but I am more comfortable doing it that way. As of the close today, that would cost $1.39 for the puts and $1.70 for the calls, a total of $309 + commission if you bought one of each. Might be fun. The danger of course is a delay by the FDA in making a decision – especially if they give no indication of which way they are leaning. Our $309 or more goes up in smoke while the FDA fiddles.

  13. Meg in Minneapolis
    Jun 19 2012, 04:32:04 am

    Two years ago, I rode ARNA up to the Advisory Committee meeting, and experienced the stock-price plunge after it. This year, I am on board again, mostly in July and January options…for astounding gains. Doctors have strongly agitated for approval of ARNA’s weight-loss drug, due to its remarkable safety. The drug also has a positive effect on diabetes. Manufacturing is ready to go, with sales possible by August. About that time, it comes up for European approval and sales, also. From my perspective, the gain could be so great between now and January that I’d risk a bit of money (or a lot) on it.

  14. Jeff Bryan
    Jun 19 2012, 06:51:46 am

    Buy and hold till the 26th and then take your “profits” while keeping a small percentage IN ACTION. Then wait 3-4 days after the 27th for the results to shake out. These biotechs scare me too much to leave all to chance. Since there are really no other good candidates in their pipeline this one (Arena) is much more risky than VVUS. By the way, my WHINE story is, I held 3000 shares of Arena for 3 and half years and sold them 3 weeks before the pop to 6.00. WHOOPS……….We all have that story don’t we.
    Thanks for all you do again Travis.

    “Irregular” Jeff

  15. bmc123
    Jun 19 2012, 11:58:28 am

    I own ARNA already – up 534% so far. I believe the situation has changed a lot since 2010 and therefore it will be approved. It’s the safest of the three, which should make approving it a no-brainer. GL if you still decide to get in before 27th.

  16. traydon
    Jun 19 2012, 07:44:50 pm

    Here’s a comparison I wrote yesterday regarding ARNA and VVUS. Since then I am even more sure that ARNA will get approval next week because we are less than a week from the PDUFA date:
    VVUS: pros: 1) has an approved ED drug that works faster than other ED drugs.
    VVUS: cons: that ED drug will face stiff competition from generics as other ED drugs soon losing patent production 2) bad side effects 3) may be prescribed as 2 generics instead of VVUS’s proprietary combination 4) the combination may be owned by JNJ and not VVUS 5) not good for women of child-bearing age (the largest market segment) 6) will not be available from pharmacies, but only by mail-order (with pregnancy test for women 18 to 45) and 7) no interest from big pharma.
    ARNA cons: no approved drug (this may vanish in less than 2 weeks)
    ARNA pros 1) robust pipeline 2) no side effects 3) no generic equivalent for many years 4) no question of patent ownership plus patent on lor-phen 5) will dominate largest market segment (women 18 to 45) 6) will be available from pharmacies, 7) an experienced pharma partner signed up and drooling to let its sales reps push its next blockbuster to replace its 2 blockbusters on the verge of losing patent protection 8) a great drug for reducing A1c a full point (25% reduction in risk of complications from diabetes incl blindness, amputation, ED, kidney failure, stroke) 9) maybe lorc helps with depression, nail-biting, smoking cessation and cessation of alcohol and other drug abuse.

  17. Fabian
    Jun 20 2012, 09:55:49 pm

    And the recommendation is to overweight an obesity drug. But ARNA seems to be a serious candidate and is pretty widely followed. Up a lot today.

  18. John
    Jun 21 2012, 09:54:59 am

    Nah, movement has already happened for these, may jump a tick or so, but think this news is the big movement catalyst for these two. We’ll have to see 🙂

  19. Mial
    Jun 22 2012, 07:31:04 am

    Does anyone know if there is a part of the FDA website which clearly lists companies / drugs awaiting approval? I’ve found past approvals but nought else! Many thanks in advance for any info.

  20. AlterIn
    Jun 22 2012, 12:06:56 pm

    More like a better idea before the 1st of April, rather than “would have been a better idea two weeks ago”, because even with today’s substantial drop in price it was ~ 2x cheaper then.

  21. Dave
    Jun 23 2012, 11:53:59 am

    From the wiki entry on lorcaserin: “Upon discontinuation of lorcaserin treatment, lost weight is regained. In Phase 2 clinical trials, patients were tracked for 2 weeks post trial completion, and all groups regained weight more rapidly than they had lost.[13] In pre-clinical trial studies, the weight of rats returned to control levels.[7]”
    If true, this drug would presumably become a permanent feature of a patient’s life. Good for sales. Too bad the data do not show that there is some effect in changing eating habits, which is what is really needed.
    The wiki article is a good read. Example: “Trial participants found lorcaserin about as tolerable as placebo, with 7% of participants in both the lorcaserin drug and placebo arms dropping out due to side effects.” Side-effects from placebo? No, and this is why blind studies are necessary.

  22. Charles Uray
    Jun 23 2012, 11:58:04 am

    There is a very simple way to lose weight and not go hungry. Do not eat any foods prepared with white flour or white sugar. All else is fair game for a meal. Lose weight and not go hungry. I have used this “diet” and lost 40 pounds in eight months and never went hungry. I also did some walking for exercise, minimum one mile per day. Not too tough a regime. It works.

    • Glenn Lidstone
      Jun 25 2012, 11:35:41 pm

      If it’s white, it ain’t right. Avoid flour, white bread, white rice, potatoes, sugar. They’re all white.
      Avoid pop (sugar). Avoid the nasty fats particularly deep fried food. Umm…hot dogs. Nope. Fries? Obviously not.
      Anything that ‘lives’ for months? Isn’t food, right? Avoid. e.g. Margarine. Even flies won’t touch it. Use butter.
      And drink lots of water.
      And that walking that Charles talks about? Awesome.

    • Bob
      Jun 29 2012, 12:37:55 pm

      That was a great call Travis!! I played the bet on the 27th and cashed out that afternoon with a 27% gain. I wish I could do that all of the time 🙂 I’m a new irregular and enjoy your commentary. Keep the nice work.

  23. Thomas E Stanley
    Mar 23 2016, 01:48:55 am

    The question as I see it is how valid is MMP. Don’t waste your money, even if it looks good now in a short period of months they will change their format completely. I was strictly a stock investor and they have changed to about 75% options. and they continue to harp about the huge percentage of gains, well a 200% gain on 2 dollars aint much. Al;so their customer service is of no help unless you want to withdraw from that passport club. They also claim to have sent a letter regarding fees , which never arrived; an email about the same thing, that never arrived then clime that the USPS is messing up again – well how does that affect email? I could go on…

What These Icons Mean